Key Points
- Chairman Paul Elliot Mann sold 162,153 shares on Dec. 1 at an average price of $5.75 for about $932,380, reducing his stake by 2.05% to 7,759,538 shares and adding to prior sales in November and September that totalled several hundred thousand shares.
- ASP Isotopes is currently unprofitable—shares opened at $5.73 with a market cap of $635.1M and a negative P/E—and the company reported Q3 EPS of ($0.15) that missed estimates despite revenue beating consensus; the stock trades below its 50- and 200-day averages (~$8.8) and has a 12-month range of $3.65–$14.49.
- Market views are mixed: analysts' average target is $13 with a consensus rating of "Hold" (two Buys, one Sell), while institutional investors like Rovida, Marshall Wace and Vanguard have recently built sizable positions, leaving institutions owning 16.8% of the stock.
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Chairman Paul Elliot Mann sold 162,153 shares of ASP Isotopes stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.75, for a total transaction of $932,379.75. Following the completion of the transaction, the chairman owned 7,759,538 shares in the company, valued at $44,617,343.50. This trade represents a 2.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Paul Elliot Mann also recently made the following trade(s):
- On Tuesday, November 25th, Paul Elliot Mann sold 50,000 shares of ASP Isotopes stock. The stock was sold at an average price of $5.77, for a total transaction of $288,500.00.
- On Monday, November 17th, Paul Elliot Mann sold 112,500 shares of ASP Isotopes stock. The shares were sold at an average price of $7.51, for a total value of $844,875.00.
- On Monday, September 8th, Paul Elliot Mann sold 81,076 shares of ASP Isotopes stock. The stock was sold at an average price of $8.53, for a total value of $691,578.28.
- On Tuesday, September 9th, Paul Elliot Mann sold 81,077 shares of ASP Isotopes stock. The stock was sold at an average price of $8.39, for a total value of $680,236.03.
ASP Isotopes Price Performance
Shares of NASDAQ:ASPI opened at $5.73 on Thursday. The company has a market cap of $635.11 million, a price-to-earnings ratio of -4.41 and a beta of 3.41. The business has a 50 day moving average price of $8.85 and a 200 day moving average price of $8.78. The company has a quick ratio of 6.10, a current ratio of 6.14 and a debt-to-equity ratio of 1.04. ASP Isotopes Inc. has a twelve month low of $3.65 and a twelve month high of $14.49.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last issued its quarterly earnings results on Wednesday, November 19th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05). ASP Isotopes had a negative return on equity of 190.44% and a negative net margin of 1,259.12%.The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $2.25 million. Research analysts predict that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on ASPI shares. Loop Capital set a $15.00 target price on shares of ASP Isotopes in a research note on Monday, October 27th. Cantor Fitzgerald assumed coverage on shares of ASP Isotopes in a report on Thursday. They set an "overweight" rating and a $13.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ASP Isotopes in a research report on Monday. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $11.00 target price on shares of ASP Isotopes in a research note on Monday, November 24th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $13.00.
Get Our Latest Research Report on ASP Isotopes
Institutional Investors Weigh In On ASP Isotopes
Institutional investors have recently bought and sold shares of the business. Rovida Advisors Inc. bought a new stake in ASP Isotopes in the 2nd quarter valued at $16,148,000. Rovida Investment Management Ltd boosted its position in shares of ASP Isotopes by 528.6% during the 2nd quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company's stock valued at $16,148,000 after acquiring an additional 1,850,000 shares in the last quarter. Exchange Traded Concepts LLC bought a new stake in ASP Isotopes in the second quarter valued at about $9,593,000. Marshall Wace LLP increased its stake in ASP Isotopes by 3,669.1% in the third quarter. Marshall Wace LLP now owns 1,279,121 shares of the company's stock valued at $12,305,000 after acquiring an additional 1,245,184 shares during the period. Finally, Vanguard Group Inc. raised its position in ASP Isotopes by 37.9% in the third quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company's stock worth $43,451,000 after purchasing an additional 1,241,024 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company's stock.
About ASP Isotopes
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
